These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34115782)

  • 1. Hybrid 2-[18F] FDG PET/MRI in premanifest Huntington's disease gene-expansion carriers: The significance of partial volume correction.
    Hellem MNN; Vinther-Jensen T; Anderberg L; Budtz-Jørgensen E; Hjermind LE; Larsen VA; Nielsen JE; Law I
    PLoS One; 2021; 16(6):e0252683. PubMed ID: 34115782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Striatal hypometabolism in premanifest and manifest Huntington's disease patients.
    López-Mora DA; Camacho V; Pérez-Pérez J; Martínez-Horta S; Fernández A; Sampedro F; Montes A; Lozano-Martínez GA; Gómez-Anson B; Kulisevsky J; Carrió I
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2183-2189. PubMed ID: 27349245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Striatal molecular alterations in HD gene carriers: a systematic review and meta-analysis of PET studies.
    Niccolini F; Pagano G; Fusar-Poli P; Wood A; Mrzljak L; Sampaio C; Politis M
    J Neurol Neurosurg Psychiatry; 2018 Feb; 89(2):185-196. PubMed ID: 28889093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Huntingtin silencing delays onset and slows progression of Huntington's disease: a biomarker study.
    Liu H; Zhang C; Xu J; Jin J; Cheng L; Miao X; Wu Q; Wei Z; Liu P; Lu H; van Zijl PCM; Ross CA; Hua J; Duan W
    Brain; 2021 Nov; 144(10):3101-3113. PubMed ID: 34043007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease.
    Russell DS; Barret O; Jennings DL; Friedman JH; Tamagnan GD; Thomae D; Alagille D; Morley TJ; Papin C; Papapetropoulos S; Waterhouse RN; Seibyl JP; Marek KL
    JAMA Neurol; 2014 Dec; 71(12):1520-8. PubMed ID: 25322077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thalamic metabolism and symptom onset in preclinical Huntington's disease.
    Feigin A; Tang C; Ma Y; Mattis P; Zgaljardic D; Guttman M; Paulsen JS; Dhawan V; Eidelberg D
    Brain; 2007 Nov; 130(Pt 11):2858-67. PubMed ID: 17893097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease.
    Antonini A; Leenders KL; Spiegel R; Meier D; Vontobel P; Weigell-Weber M; Sanchez-Pernaute R; de Yébenez JG; Boesiger P; Weindl A; Maguire RP
    Brain; 1996 Dec; 119 ( Pt 6)():2085-95. PubMed ID: 9010012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cortical atrophic-hypometabolic dissociation in the transition from premanifest to early-stage Huntington's disease.
    Sampedro F; Martínez-Horta S; Perez-Perez J; Horta-Barba A; Lopez-Mora DA; Camacho V; Fernández-León A; Gomez-Anson B; Carrió I; Kulisevsky J
    Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1111-1116. PubMed ID: 30627816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study.
    Feigin A; Leenders KL; Moeller JR; Missimer J; Kuenig G; Spetsieris P; Antonini A; Eidelberg D
    J Nucl Med; 2001 Nov; 42(11):1591-5. PubMed ID: 11696626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study.
    Politis M; Pavese N; Tai YF; Kiferle L; Mason SL; Brooks DJ; Tabrizi SJ; Barker RA; Piccini P
    Hum Brain Mapp; 2011 Feb; 32(2):258-70. PubMed ID: 21229614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping the order and pattern of brain structural MRI changes using change-point analysis in premanifest Huntington's disease.
    Wu D; Faria AV; Younes L; Mori S; Brown T; Johnson H; Paulsen JS; Ross CA; Miller MI;
    Hum Brain Mapp; 2017 Oct; 38(10):5035-5050. PubMed ID: 28657159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis of Huntington's disease via sequential 18F-DOPA and 18F-FDG PET/MRI.
    Michler E; Hoberück S; Martino F; Platzek I; Kotzerke J
    Nuklearmedizin; 2019 Sep; 58(5):403-404. PubMed ID: 31344728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal Imaging of Regional Brain Volumes, SV2A, and Glucose Metabolism In Huntington's Disease.
    Delva A; Van Laere K; Vandenberghe W
    Mov Disord; 2023 Aug; 38(8):1515-1526. PubMed ID: 37382295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease.
    Niccolini F; Haider S; Reis Marques T; Muhlert N; Tziortzi AC; Searle GE; Natesan S; Piccini P; Kapur S; Rabiner EA; Gunn RN; Tabrizi SJ; Politis M
    Brain; 2015 Oct; 138(Pt 10):3016-29. PubMed ID: 26198591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease.
    Ciarmiello A; Cannella M; Lastoria S; Simonelli M; Frati L; Rubinsztein DC; Squitieri F
    J Nucl Med; 2006 Feb; 47(2):215-22. PubMed ID: 16455626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG μPET Fails to Detect a Disease-Specific Phenotype in Rats Transgenic for Huntington's Disease – A 15 Months Follow-up Study.
    Reilmann R; Lippross V; Hölzner E; Gigengack F; Bohlen S; Kugel H; Deppe M; Osada N; Lücke M; Riess O; Nguyen HP; Von Hörsten S; Schäfers K; Schäfers M; Jacobs AH; Hermann S
    J Huntingtons Dis; 2015; 4(1):37-47. PubMed ID: 26333256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnetization transfer imaging in 'premanifest' Huntington's disease.
    Jurgens CK; Bos R; Luyendijk J; Witjes-Ané MN; van der Grond J; Middelkoop HA; Roos RA
    J Neurol; 2010 Mar; 257(3):426-32. PubMed ID: 19823894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic network as a progression biomarker of premanifest Huntington's disease.
    Tang CC; Feigin A; Ma Y; Habeck C; Paulsen JS; Leenders KL; Teune LK; van Oostrom JC; Guttman M; Dhawan V; Eidelberg D
    J Clin Invest; 2013 Sep; 123(9):4076-88. PubMed ID: 23985564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers.
    Wilson H; Niccolini F; Haider S; Marques TR; Pagano G; Coello C; Natesan S; Kapur S; Rabiner EA; Gunn RN; Tabrizi SJ; Politis M
    J Neurol Sci; 2016 Sep; 368():243-8. PubMed ID: 27538642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between CAG repeat length and brain volume in premanifest and early Huntington's disease.
    Henley SM; Wild EJ; Hobbs NZ; Scahill RI; Ridgway GR; Macmanus DG; Barker RA; Fox NC; Tabrizi SJ
    J Neurol; 2009 Feb; 256(2):203-12. PubMed ID: 19266143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.